NCT01597375View on ClinicalTrials.gov

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 14, 2016

Study Completion Date

December 14, 2016

Conditions
Asthma, Aspirin-InducedAspirin Exacerbated Asthma
Interventions
DRUG

Placebo Oral Tablet

Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

DRUG

Prasugrel Oral Tablet

Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Trial Locations (1)

02115

Asthma Research Center, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Elliot Israel, MD

OTHER

NCT01597375 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin) | Biotech Hunter | Biotech Hunter